Overall neutralization of complement factor H by autoantibodies in the acute phase of the autoimmune form of atypical hemolytic uremic syndrome.
about
Complement System Part II: Role in ImmunityHaemolytic uraemic syndrome.Complement therapy in atypical haemolytic uraemic syndrome (aHUS).Long-term remission of atypical HUS with anti-factor H antibodies after cyclophosphamide pulses.Successful treatment of DEAP-HUS with eculizumab.[Pathophysiology of atypical hemolytic uremic syndrome. Ten years of progress, from laboratory to patient].Outcomes of renal transplant in patients with anti-complement factor H antibody-associated hemolytic uremic syndrome.The major autoantibody epitope on factor H in atypical hemolytic uremic syndrome is structurally different from its homologous site in factor H-related protein 1, supporting a novel model for induction of autoimmunity in this disease.Overactivation of Complement Alternative Pathway in Postpartum Atypical Hemolytic Uremic Syndrome Patients with Renal Involvement.Anti-complement-factor H-associated glomerulopathies.Microbes bind complement inhibitor factor H via a common siteA Familial C3GN Secondary to Defective C3 Regulation by Complement Receptor 1 and Complement Factor HStaphylococcal protein Ecb impairs complement receptor-1 mediated recognition of opsonized bacteria.Effect of complement Factor H on anti-FHbp serum bactericidal antibody responses of infant rhesus macaques boosted with a licensed meningococcal serogroup B vaccineAssociation among Complement Factor H Autoantibodies, Deletions of CFHR, and the Risk of Atypical Hemolytic Uremic Syndrome.Analysis of Linear Antibody Epitopes on Factor H and CFHR1 Using Sera of Patients with Autoimmune Atypical Hemolytic Uremic Syndrome.Making sense of the spectrum of glomerular disease associated with complement dysregulation.Kidney Disease Caused by Dysregulation of the Complement Alternative Pathway: An Etiologic Approach.Endothelial cells: source, barrier, and target of defensive mediators.Complement C5-inhibiting therapy for the thrombotic microangiopathies: accumulating evidence, but not a panacea.Factor H autoantibody is associated with atypical hemolytic uremic syndrome in children in the United Kingdom and IrelandDiseases of complement dysregulation-an overview.Thrombotic Microangiopathy and the Kidney.Functional Characterization of the Disease-Associated N-Terminal Complement Factor H Mutation W198R.Characterization of genetic predisposition and autoantibody profile in atypical haemolytic-uraemic syndrome.The clinical and laboratory features of Chinese Han anti-factor H autoantibody-associated hemolytic uremic syndrome.Atypical hemolytic uremic syndromeHemolytic uremic syndrome
P2860
Q28263460-339E1B55-7335-48D9-AECB-77EC0EED5EE8Q30244707-3E347174-0A99-4121-92E3-AD73598319C2Q33408733-74E59F73-4029-4414-8DEF-4318F711D575Q33409198-1F411D80-B46E-4BE8-A730-8C1FDF649E76Q33411577-DE5C78AE-2E89-4AD4-B62B-55CE4BE6787FQ33413660-D412155E-2789-4E34-93AE-B55208D68B37Q33415192-DCECCCD5-9716-4CDE-B9C0-E8D041FB9BECQ33420213-5FA569CB-D701-4C64-BD14-DC01E86693C6Q33423118-4BE187F5-6DC3-40F8-AF06-F52D7BEE98ADQ33434103-CC8208C4-1D5C-4C17-889D-F5ADCF002CFDQ34699715-12CEE550-F303-44FC-BE3D-24F2B5897809Q35809292-05CC8DFD-4548-4561-B1C6-6FA6A2147FBEQ36300934-5CA2CFFF-DF01-4847-80AA-8C43A7B2923CQ36385023-E2628AF3-29ED-4759-BCD5-2B376DB25182Q37546464-A5E4F752-FED1-4782-AC1F-5FCF28F95F04Q37727489-442CA46B-3093-42F0-B913-92F208F396ABQ38121480-7F210342-66F5-4604-82DC-707936B42D2BQ38549182-94A398B1-8AE6-48C3-9CCE-A43CEEA125A8Q38991026-E324FC20-1B35-4E6E-831A-9BD5200F5923Q42086661-D528E47A-ACEB-4077-ADA8-8C1C0C25C699Q42650328-DB51C9B4-770D-470E-BDA2-8F83228B6424Q48256943-3AF1093D-7DCF-4880-8BDD-FF4E1AD8DDA6Q50085453-48014C4A-B3DB-4742-8FAF-15AC13183607Q50100348-22973B58-397A-4FFD-A309-86D83376E23BQ52372272-E3A7D6C2-E68C-45AF-9B1B-31229CE0F9C6Q52767922-E70C9F63-AC8B-47FD-9F20-8B277BC3E346Q56591965-0A6AD428-F018-4932-B778-C79B75218C95Q57701679-CC31255F-BC3C-4048-92AA-3A3B4D7C8FB9
P2860
Overall neutralization of complement factor H by autoantibodies in the acute phase of the autoimmune form of atypical hemolytic uremic syndrome.
description
2012 nî lūn-bûn
@nan
2012 թուականի Օգոստոսին հրատարակուած գիտական յօդուած
@hyw
2012 թվականի օգոստոսին հրատարակված գիտական հոդված
@hy
2012年の論文
@ja
2012年学术文章
@wuu
2012年学术文章
@zh-cn
2012年学术文章
@zh-hans
2012年学术文章
@zh-my
2012年学术文章
@zh-sg
2012年學術文章
@yue
name
Overall neutralization of comp ...... cal hemolytic uremic syndrome.
@ast
Overall neutralization of comp ...... cal hemolytic uremic syndrome.
@en
type
label
Overall neutralization of comp ...... cal hemolytic uremic syndrome.
@ast
Overall neutralization of comp ...... cal hemolytic uremic syndrome.
@en
prefLabel
Overall neutralization of comp ...... cal hemolytic uremic syndrome.
@ast
Overall neutralization of comp ...... cal hemolytic uremic syndrome.
@en
P2093
P50
P356
P1476
Overall neutralization of comp ...... cal hemolytic uremic syndrome.
@en
P2093
Arvind Bagga
Ashima Gulati
Bruno Ranchin
Caroline Blanc
Chantal Loirat
Patrick Niaudet
Satu Hyvärinen
Sidharth Kumar Sethi
T Sakari Jokiranta
Véronique Frémeaux-Bacchi
P304
P356
10.4049/JIMMUNOL.1200679
P407
P50
P577
2012-08-24T00:00:00Z